Asymptomatic occlusive retinal vasculitis in newly diagnosed active tuberculosis.

Ophthalmology Retina Tuberculosis Vasculitis

Journal

Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463

Informations de publication

Date de publication:
2021
Historique:
received: 19 01 2021
revised: 23 04 2021
accepted: 15 06 2021
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 18 8 2021
Statut: epublish

Résumé

Worldwide, tuberculosis is the leading cause of death from an infectious disease. Ocular involvement can cause significant and permanent vision loss. Ocular manifestations of tuberculosis often present with visual symptoms. Asymptomatic ocular tuberculosis is uncommon and yet can have serious consequences if missed. An immunocompetent 26-year-old Filipino man living in regional Australia who was diagnosed with active pulmonary tuberculosis and started on antitubercular therapy. He was referred to an ophthalmologist for baseline ethambutol screening to exclude pre-existing optic neuropathy. Despite having no visual symptoms, when examined, the patient had vision threatening occlusive retinal vasculitis. He was initially commenced on localised therapy via bevacizumab intravitreal injections and retinal photocoagulation. Following completion of antitubercular therapy, high dose prednisone was commenced and slowly tapered. We present the case of an asymptomatic sight threatening occlusive vasculitis that was discovered on pre-treatment ophthalmology review. This case emphasises the need for referral for full ophthalmic screening in newly diagnosed tuberculosis to exclude vision-threatening complications.

Identifiants

pubmed: 34401294
doi: 10.1016/j.rmcr.2021.101456
pii: S2213-0071(21)00118-0
pmc: PMC8349080
doi:

Types de publication

Case Reports

Langues

eng

Pagination

101456

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

We declare no competing or conflicts of interests. All authors were involved in conception, writing and critical review of the report. Informed consent was obtained from the patient for the publication of the clinical pictures and case report. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit-sectors.

Références

Curr Opin Ophthalmol. 2017 Nov;28(6):545-551
pubmed: 28759559
Clin Exp Ophthalmol. 2018 Jan;46(1):62-74
pubmed: 28557287
Clin Exp Ophthalmol. 2017 May;45(4):357-365
pubmed: 27896896
Eye (Lond). 2013 Apr;27(4):480-6
pubmed: 23429412
Am J Ophthalmol. 2008 Nov;146(5):772-9
pubmed: 18708180
Am J Ophthalmol. 2010 Apr;149(4):562-70
pubmed: 20149341
Arch Ophthalmol. 2005 Jun;123(6):844-9
pubmed: 15955987
Curr Opin Rheumatol. 2016 May;28(3):228-35
pubmed: 26945335
Br J Ophthalmol. 2014 Jun;98(6):785-9
pubmed: 24511084
Eye (Lond). 2011 Apr;25(4):475-80
pubmed: 21293496
Ocul Immunol Inflamm. 2015 Feb;23(1):14-24
pubmed: 25615807
JAMA Ophthalmol. 2017 Dec 1;135(12):1318-1327
pubmed: 29075752
Clin Exp Ophthalmol. 2012 Sep-Oct;40(7):689-96
pubmed: 22299676
Ophthalmology. 2021 Feb;128(2):277-287
pubmed: 32603726
Ther Clin Risk Manag. 2013;9:9-26
pubmed: 23326198

Auteurs

Christopher Bartimote (C)

Ophthalmology, Royal North Shore Hospital, Sydney, Australia.
The University of Sydney, Sydney, Australia.

Samantha Fraser-Bell (S)

Ophthalmology, Royal North Shore Hospital, Sydney, Australia.
Ophthalmology, Sydney Eye Hospital, Sydney, Australia.
The University of Sydney, Sydney, Australia.

Hamish Dunn (H)

Port Macquarie Eye Centre, Port Macquarie, Australia.
The University of Sydney, Sydney, Australia.

Classifications MeSH